Skip to main content
. 2022 Jan 6;12(1):e052880. doi: 10.1136/bmjopen-2021-052880

Table 4.

Power calculation at a constant sample size of 490, allowing for varying percentage declines in creatinine clearance (CrCl) estimates in the TAF implant and TDF/FTC oral groups

Mean CrCl % decline in TDF/FTC group
3 4 5 6 7
Mean CrCl % decline in the TAF group 0.5 56 84 >95 >95 >95
1 39 72 90 >95 >95
1.5 24 56 84 >95 >95

TAF, tenofovir alafenamide; TDF/FTC, tenofovir disoproxil fumarate and emtricitabine.